Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1480"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label |
"evidence_1300"
|
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
""Biotransformation pathways elucidated for pravastatin include: (a) isomerization to 6-epi pravastatin and the 3alpha-hydroxyisomer of pravastatin (SQ 31,906), (b) enzymatic ring hydroxylation to SQ 31,945, (c) omega-1 oxidation of the ester side chain, (d) beta-oxidation of the carboxy side chain, (e) ring oxidation followed by aromatization, (f) oxidation of a hydroxyl group to a keto group, and (g) conjugation. The major degradation product is the 3alpha-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.""
|
| dc:creator | |
| dc:date |
"10/29/2007 11:50:24"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ pravastatin_has_metabolite_3alpha-hydroxypravastatin, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1300 }